 |
 |
The Michael J. Fox Foundation has awarded a grant to Civitas Therapeutics for clinical trials of CVT-301, which is a new inhaled version of L-dopa. It is claimed that CVT-301 has the potential to produce rapid, consistent and durable relief from the motor fluctuations associated with Parkinson’s Disease. Civitas has conducted a range of preclinical studies demonstrating CVT-301’s ability to deliver more rapid and consistent systemic exposure of L- dopa compared to the oral administration of L-dopa. The efficacy of oral L- dopa is significantly compromised by delayed absorption and excessive variability in the circulating drug concentrations. It is anticipated that the inhaled version of L-dopa would be used alongside the use of oral L-dopa. For more information go to the CVT-301 uses the ARCUS inhalation technology, which delivers a reliable and consistent drug dose with a compact, breath actuated inhaler. It uses a proprietary dry powder and inhaler combination that is unique in its ability to deliver a large, precise dose independent of inspiratory flow rate from a simple, easy-to-use device suitable for convenient self-administration. The platform has successfully delivered more than one million doses to patients incorporating active agents ranging from small molecules to large proteins. http://viartis.net/parkinsons.disease/news.htm ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn